Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The role of p53 protein and MMP-2 tumor/stromal cells expression on progressive growth of ovarian neoplasms.

Grelewski PG, Bar JK.

Cancer Invest. 2013 Aug;31(7):472-9. doi: 10.3109/07357907.2013.820320.

PMID:
23915071
2.

Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM.

Eur J Cancer. 2001 Nov;37(16):2040-9.

PMID:
11597382
3.

[Clinical significance of matrix metalloproteinase-2 expression in patients with epithelial ovarian tumor].

Wu X, Li H, Song J.

Zhonghua Fu Chan Ke Za Zhi. 2001 Oct;36(10):621-4. Chinese.

PMID:
16134528
4.

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IeM, Kurman RJ.

Mod Pathol. 2011 Sep;24(9):1248-53. doi: 10.1038/modpathol.2011.85. Epub 2011 May 6.

5.

Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer.

Wu X, Li H, Kang L, Li L, Wang W, Shan B.

Gynecol Oncol. 2002 Jan;84(1):126-34.

PMID:
11748988
6.
7.

Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.

Drew AF, Blick TJ, Lafleur MA, Tim EL, Robbie MJ, Rice GE, Quinn MA, Thompson EW.

Gynecol Oncol. 2004 Dec;95(3):437-48.

PMID:
15581944
8.
9.

p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.

Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A.

Cancer Biol Ther. 2002 Sep-Oct;1(5):511-7.

PMID:
12496479
10.

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Apr;25(4):615-24. doi: 10.1038/modpathol.2011.189. Epub 2011 Dec 9.

11.

[P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].

Casper F, Weikel W, Schaffrath M, Kuner RP, Hoffmann G, Pollow B, Pollow K.

Zentralbl Gynakol. 2000;122(3):153-9. German.

PMID:
10756599
12.

The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.

Lassus H, Butzow R.

Br J Cancer. 2007 May 21;96(10):1621-2; author reply 1623-4. Epub 2007 Apr 17. No abstract available.

13.
14.

Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.

Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, Kristensen GB, Bryne M, Reich R.

Am J Surg Pathol. 2001 Dec;25(12):1493-500. Erratum in: Am J Surg Pathol 2002 Apr;26(4):539.

PMID:
11717538
15.

p53 mutation is infrequent in clear cell carcinoma of the ovary.

Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS.

Gynecol Oncol. 2001 Feb;80(2):189-93.

PMID:
11161858
16.

[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].

Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.

Ai Zheng. 2004 Oct;23(10):1194-8. Chinese.

PMID:
15473934
17.

Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression.

Long L, Cao Y, Tang LD.

Int J Gynecol Cancer. 2012 May;22(4):539-45. doi: 10.1097/IGC.0b013e318247323d.

PMID:
22495744
18.

Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.

Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC.

Gynecol Oncol. 2000 Jun;77(3):369-76.

PMID:
10831344
19.

The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations.

Olcha P, Cybulski M, Skomra D, Obrzut B, Ignatov A, Jóźwik M, Schneider-Stock R, Semczuk A.

Int J Gynecol Cancer. 2010 Aug;20(6):993-9. doi: 10.1111/IGC.0b013e3181e76a4d.

PMID:
20683407
20.

Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.

Liu FS, Dong JT, Chen JT, Hsieh YT, Ho ES, Hung MJ.

Gynecol Oncol. 2000 Jul;78(1):10-5.

PMID:
10873402

Supplemental Content

Support Center